Primary cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of lymphomas
that present in the skin with no evidence of extracutaneous disease at the time of diagnosis …

On behalf of the EORTC Cutaneous Lymphoma Tumours Group (EORTC-CLTG) and
following up on earlier versions published in 2006 and 2017 this document provides an …

Cutaneous T cell lymphomas (CTCL) are rare but aggressive cancers without effective
treatments. While a subset of patients derive benefit from PD-1 blockade, there is a critically …

Abstract Disease Overview Cutaneous T‐cell lymphomas are a heterogenous group of T‐
cell neoplasms involving the skin, the majority of which may be classified as Mycosis …

Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …

Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of orphan neoplasms.
Despite the introduction of anthracycline-based chemotherapy protocols, with or without …

Cutaneous T cell lymphoma (CTCL) is characterized by the accumulation of malignant T
cells in the skin. However, advanced CTCL pathophysiology remains elusive and …

As the incidence of cutaneous malignancies continues to rise and their treatment with
immunotherapy expands, dermatologists and their patients are more likely to encounter …

Immune checkpoint inhibitors (ICIs) are immunomodulatory antibodies that intensify the host
immune response, thereby leading to cytotoxicity. The primary targets for checkpoint …

Abstract Purpose of Review Programmed cell death protein-1 (PD-1) is currently the most
extensively studied inhibitory checkpoint molecule. Many malignant neoplasms express the …